Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med. 1999;341:725–732.
Camaschella C, Roetto A, Calì A, et al. The gene encoding transferrin receptor 2 is mutated in a new type of hemochromatosis mapping to 7q22. Nat Genet. 2000;25:14–15.
Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001;108:619–623.
Pietrangelo A, Caleffi A, Herion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128:470–479.
Montosi G, Corradini E, Garuti C, et al. Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology. 2005;41:545–552.
Pietrangelo A, Dierssen U, Valli L, et al. STAT3 is required for IL-6–gp130–dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–308.
Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134:226–238.
Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–487.
Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science. 2009;325:877–880.
Corradini E, Schmidt PJ, Meynard D, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology. 2010;139:172–181.
Vecchi C, Montosi G, Pietrangelo A, et al. Huh-7: a human “hemochromatotic” cell line. Hepatology. 2010;51:654–659.
Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology. 2014;146:1060–1069.
Sonnweber T, Nachbaur D, Schroll A, et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut. 2014;63:1951–1959.
Canali S, Vecchi C, Garuti C, et al. The SMAD pathway is required for hepcidin response during endoplasmic reticulum stress. Endocrinology. 2016;157:3935–3945.
Sabelli M, Montosi G, Garuti C, et al. Human macrophage ferroportin biology and the basis for the ferroportin disease. Hepatology. 2017;65:1512–1525.
Brissot P, Pietrangelo A, Adams PC, et al. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016.
Buzzetti E, Petta S, Manuguerra R, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int. 2019;39:1325–1334.
Balwani M, Sardh E, Ventura P, et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020;382:2289–2301.
Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021;75:506–513.
Ekaputri S, Choi EK, Sabelli M, et al. A small molecule redistributes iron in ferroportin-deficient mice and patient-derived primary macrophages. Proc Natl Acad Sci U S A. 2022;119:e2121400119.
Vecchi C, Montosi G, Garuti C, et al. CREB-H is a stress-regulator of hepcidin gene expression during early postnatal development. J Mol Med. 2023;101:1113–1124.
Valenti L, Corradini E, Adams LA, et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol. 2023;19:299–310.
Ricci A, Corradini E, Buzzetti E, et al. Porphyrias: Pathophysiology and clinical management recommendations for hepatologists. Hepatol Commun. 2025;9:e0822.
Ricci A, Pasquinelli M, Carusi A, et al. Alterations in iron status predict cardiac response to blood transfusion in β-thalassemia major. Sci Rep. 2025;16:1898.
Ricci A, Andolfi F, Sabbatini D, et al. Genome-wide association for sarcoidosis identifies novel risk loci. Orphanet J Rare Dis. 2025;20:638.
Leaf RK, Ricci A, Tran B, et al. Haematological parameters in erythropoietic protoporphyria: A multi national study. Br J Haematol. 2025;201:20197.
Anderlini A, Sabelli M, Corradini E, et al. Lipidic nanomedicines enhance Hinokitiol activity on human primary macrophages from Ferroportin disease patients. Int J Pharm. 2026;689:126487.